Hypertension

Tamura discusses the positive results of the phase 2 trial and its implications for the treatment of a specific subset of patients with high-sensitivity IL-6 PAH.

Whelton discusses the successful results of an open-label extension investigating GMRx2 (WIDAPLIK), a novel triple combination pill for hypertension.

McLaughlin discussed the previous ZENITH, PULSAR, and STELLAR trials, and how this pooled cohort analysis emphasizes sotatercept’s impressive efficacy.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Recent research has highlighted the influence of minor beat-to-beat changes in blood pressure on the left side of the brain.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Preeclampsia, gestational diabetes, preterm delivery, large for gestational age, and other hypertensive disorders of pregnancy are now risk factors.

The phase 3 ZENITH trial showed sotatercept’s superiority over placebo in reducing morbidity and mortality outcomes in adults with WHO FC III or IV PAH.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

Vaidya describes the prognostic approach to pulmonary hypertension in the revised Echocardiographic Assessment of the Right Heart Guidelines.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

The investigative therapy for treatment-resistant hypertension resulted in a substantial reduction in ambulatory 24-hour average systolic blood pressure versus placebo.

Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

Wang and colleagues analyzed data from nearly 105,000 patients to create and test a device that can predict the efficacy of various drug combinations for hypertension.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

The death rate from high blood pressure-related kidney disease increased by 48% from 1999-2023, with notable disparities by race, ethnicity, sex, and region.

Patel addresses the updated AHA/ACC hypertension guidelines, explaining important features and highlighting the potential of newer therapies.

Bhalla breaks down the newer treatments included in the recently updated AHA/ACC hypertension management guidelines.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.